RedHill Biopharma appeals Nasdaq delisting notice

Go back to RedHill Biopharma appeals Nasdaq delisting notice

RedHill Biopharma Receives Nasdaq Staff Determination Notification

October 22, 2025 4:50 PM UTC

On October 16, 2025, the Company received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with the minimum stockholders' equity requirements for continued listing, pursuant to Listing Rule 5550(b)(1) 

Following RedHill's transaction with Cumberland Pharmaceuticals Inc., announced October 20, 2025, the Company believes that its stockholders' equity now exceeds the minimum $2.5 million requirement and that it is well positioned to maintain compliance

 The Company intends to appeal Staff's determination to a... More